Home » Newsletters » BioWorld Science

BioWorld Science

June 20, 1997

View Archived Issues

Merck & Co. reports NOS inhibitors

5-HT2C/2A receptor antagonists from Egis

RXR-selective compounds disclosed by Allergan

Agents for psoriasis and cancers from Roche

NicOx reveals antiinflammatory/antithrombotic compounds with low toxicity

Merck & Co. discloses muscarinic antagonists for myopia

Agents for glaucoma revealed by Merck & Co.

Novel immunosuppressants prepared by Merck & Co.

Combination therapy approved by FDA for H. pylori eradication

Antifungal activity of nikkomycin Z alone and in combination with azoles

FDA advisory committee to review rituximab BLA

Crystal structure of BPI described by Xoma/UCLA

BioQuest to acquire Immune Complex Corporation

ERT reported to protect against AD

Axcan to distribute Ursofalk in Canada

Preclinical results reported by Lilly and Synaptic for potent and selective 5-HT1F agonist

Trega Biosciences and Northwest Neurologic sign drug discovery agreement

New antifungals under development

New polyene from SPA compared to amphotericin B

Hi-Tech Pharmacal obtains license to huperzine

New sordarin derivatives from Glaxo Wellcome

Agouron's IND for anticancer agent approved

Labopharm and Sepracor to develop new dosage forms of levalbuterol

Lilly and Serenics to codevelop psychopharmacologic and cardiovascular drugs

Triazole antifungals under development

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...